Fitly Health & InSyBio have partnered to create the world’s first Metabolic AI™ precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes

Fitly Health has partnered with InSyBio to deliver life-changing outcomes for patients and employees with metabolic disorders who need to lose weight. Everyone has a unique metabolism and research now shows that our metabolic health is largely affected by diet-influenced changes to our gut microbiome. In other words, existing dietary interventions would be more effective in the long-term if practitioners and dietitians first understood the type of proverbial “fuel” that’s best suited for each individual patient. Namely their gut biomarkers. It’s like telling every vehicle owner they should go to the gas pump and fill their tank up with regular fuel vs mid-grade or premium, but the reality is that most of us require premium fuel. Foods that are diverse in micronutrients, phytonutrients, and fibers needed to rebuild and sustain a healthy gut environment and fuel-efficient body.

This is why Fitly Health & InSyBio have partnered to create the world’s first “Metabolic AI™” program that’s powered by gut microbiome analysis, predictive generative AI, precision nutrition tracking, and virtual coaching for patients diagnosed with metabolic syndrome, prediabetes, and Type 2 diabetes for starters. Patients will also be incentivized to with financial incentives and rewards for adherence and completion of the 12-month program.

Fitly Health, a Miami-based precision nutrition startup, is the brain-child of Anthony Ortiz, a serial inventor who also created SmartPlate (, the world’s smartest food tracker that has been featured in the likes of Forbes, Shark Tank, and Times of London. InSyBio ( is a multi-awarded international pioneer biotechnology company expediting biomarker discovery and predictive analytics for precision medicine and nutrition applications.

“I believe the future of medicine, wellbeing, and longevity will largely depend upon the diversity and health of our gut. As a proven disruptor in precision medicine and nutrition through biomarker discovery, we couldn’t be more excited to partner with Labros, Kostas, and the illustrious team at InSyBio.” said Anthony Ortiz, CEO at Fitly Health.

“Our synergy with Fitly Health, and their unique product (SmartPlate), presents a unique opportunity for us to bring our technology into the service of precision nutrition to harness the power of AI and the gut microbiome. Precision medicine and nutrition is the enabler of better health for everyone. Efficient biomarker discovery and training of accurate outcome prediction models have been traditionally a bottleneck in precision medicine and nutrition, but our synergy with Fitly Health offers an innovative solution for this problem. We are looking forward to this exciting endeavour and we envisage a fruitful collaboration that will improve the health of millions of patients worldwide and allow technology to positively disrupt the way we eat”, stated Labros Digonis, CEO of InSyBio.

About InSyBio: InSyBio is an international pioneer biotechnology company revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery, highly-accurate predictive analytics and the development of personalization tests for drugs, nutraceuticals and nutrition products.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models).  This is done through a   sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and a decrease of at least 80% in overall time and cost.

Visit to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition. For more News visit our InSyBio Blog.

Scroll to top